- Home
- DSGR vs ETNB Comparison
DSGR vs ETNB Comparison
Compare DSGR & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGR
- ETNB
- Stock Information
- Founded
- DSGR 1952
- ETNB 2018
- Country
- DSGR United States
- ETNB United States
- Employees
- DSGR N/A
- ETNB 93
- Industry
- DSGR Industrial Machinery/Components
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- DSGR Industrials
- ETNB Health Care
- Exchange
- DSGR Nasdaq
- ETNB Nasdaq
- Market Cap
- DSGR 1.5B
- ETNB 2.2B
- IPO Year
- DSGR N/A
- ETNB 2019
- Fundamental
- Price
- DSGR $28.27
- ETNB $14.83
- Analyst Decision
- DSGR Buy
- ETNB Buy
- Analyst Count
- DSGR 1
- ETNB 10
- Target Price
- DSGR $41.00
- ETNB $22.31
- AVG Volume (30 Days)
- DSGR 70.2K
- ETNB 9.5M
- Earning Date
- DSGR 10-30-2025
- ETNB 11-06-2025
- Dividend Yield
- DSGR N/A
- ETNB N/A
- EPS Growth
- DSGR N/A
- ETNB N/A
- EPS
- DSGR 0.08
- ETNB N/A
- Revenue
- DSGR $1,928,948,000.00
- ETNB N/A
- Revenue This Year
- DSGR $11.30
- ETNB N/A
- Revenue Next Year
- DSGR $4.13
- ETNB N/A
- P/E Ratio
- DSGR $308.07
- ETNB N/A
- Revenue Growth
- DSGR 13.48
- ETNB N/A
- 52 Week Low
- DSGR $21.87
- ETNB $4.16
- 52 Week High
- DSGR $41.47
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- DSGR 33.94
- ETNB 79.17
- Support Level
- DSGR $29.18
- ETNB $14.67
- Resistance Level
- DSGR $30.56
- ETNB $14.93
- Average True Range (ATR)
- DSGR 1.06
- ETNB 0.09
- MACD
- DSGR -0.18
- ETNB 0.06
- Stochastic Oscillator
- DSGR 3.58
- ETNB 41.03
About DSGR Distribution Solutions Group Inc.
Distribution Solutions Group Inc is an industrial distributor of maintenance and repair supplies. It has three operating segments namely Lawson, TestEquity, and Gexpro Services, of which key revenue is derived from the TestEquity segment. The TestEquity segment is a distributor of test and measurement equipment and solutions, electronic production supplies, and tool kits from its manufacturer partners supporting the technology, aerospace, defense, automotive, electronics, education and medical industries.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).